Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA Stok Raporu

Piyasa değeri: US$665.0m

Olema Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Olema Pharmaceuticals's earnings are forecast to decline at 4.9% per annum while its annual revenue is expected to grow at 72.5% per year. EPS is expected to decline by 4.6% per annum. Return on equity is forecast to be -66.6% in 3 years.

Anahtar bilgiler

-4.9%

Kazanç büyüme oranı

-4.6%

EPS büyüme oranı

Biotechs kazanç büyümesi27.1%
Gelir büyüme oranı72.5%
Gelecekteki özkaynak getirisi-66.6%
Analist kapsamı

Low

Son güncelleme01 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Aug 29
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Olema Pharmaceuticals: Still Merits A Small Holding

Jun 17

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Mar 28

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04
Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Jun 11
We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Mar 01
Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Oncology grants stock options for 58.3K shares

Oct 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:OLMA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20268-174-150N/A3
12/31/2025N/A-155-137-1445
12/31/2024N/A-130-90-515
6/30/2024N/A-110-92-92N/A
3/31/2024N/A-99-87-87N/A
12/31/2023N/A-97-84-84N/A
9/30/2023N/A-96-85-85N/A
6/30/2023N/A-97-81-80N/A
3/31/2023N/A-110-85-85N/A
12/31/2022N/A-105-82-82N/A
9/30/2022N/A-100-82-81N/A
6/30/2022N/A-95-76-75N/A
3/31/2022N/A-79-59-58N/A
12/31/2021N/A-71-52-51N/A
9/30/2021N/A-60-42-41N/A
6/30/2021N/A-52-37-37N/A
3/31/2021N/A-38-29-29N/A
12/31/2020N/A-24-20-20N/A
9/30/2020N/A-15-12-12N/A
12/31/2019N/A-4-3-3N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OLMA is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: OLMA is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: OLMA is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: OLMA is forecast to have no revenue next year.

Yüksek Büyüme Geliri: OLMA is forecast to have no revenue next year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OLMA is forecast to be unprofitable in 3 years.


Büyüyen şirketleri keşfedin